Trevi Therapeutics to Present at the Leerink Partners Therapeutics Forum in Boston

Trevi Therapeutics to Attend the Leerink Partners Therapeutics Forum

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a renowned clinical-stage biopharmaceutical company, is gearing up to participate in the upcoming Leerink Partners Therapeutics Forum II and Metabolism, scheduled for July 8-9 in Boston, Massachusetts. The event will feature key leaders from Trevi, including Jennifer Good, the President and Chief Executive Officer, and Lisa Delfini, the Chief Financial Officer.

Overview of Trevi Therapeutics

The focus of Trevi Therapeutics revolves around the development of its investigational therapy, Haduvio™ (oral nalbuphine extended-release), specifically designed to address chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Haduvio is noteworthy as it has become the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials involving patients suffering from chronic cough related to IPF and RCC. The therapy has a dual mechanism of action; it operates on the cough reflex both centrally and peripherally as a kappa agonist and mu antagonist (KAMA), engaging opioid receptors that are crucial in regulating chronic cough responses. Importantly, nalbuphine is not classified as a controlled substance by the U.S. Drug Enforcement Administration, enhancing its accessibility as a treatment option.

Chronic cough is a multifaceted condition that significantly affects up to 85% of patients diagnosed with IPF. In the United States alone, it is estimated that around 150,000 individuals have IPF, with many experiencing debilitating cough episodes that can reach up to 1,500 times per day. Beyond causing physical discomfort, this relentless coughing can lead to further health complications, including the potential for disease progression and the necessity for lung transplants. Moreover, the psychological, social, and physical quality of life for these patients is often severely impacted.

Refractory chronic cough, contrastingly, lacks approved treatment alternatives in the U.S. It is characterized as a resilient cough persisting for more than eight weeks despite managing an underlying condition, which could include asthma, gastroesophageal reflux disease, or post-nasal drip. RCC is shown to affect approximately 2 to 3 million patients in the U.S. The underlying cause is often attributed to hypersensitivity in the cough reflex, impacting both central and peripheral nervous systems, leading to significant societal and financial burdens.

Trevi Therapeutics’ introduction of Haduvio aims to provide a much-needed therapeutic solution for these challenging conditions, which currently have minimal effective treatment options available on the market.

The Importance of the Leerink Partners Forum

Participation in the Leerink Partners Therapeutics Forum II holds great significance for Trevi Therapeutics, not only for its potential to showcase clinical advancements but also as a networking opportunity with various stakeholders in the healthcare sector. This event allows for invaluable discussions regarding future directions in treatment protocols and biopharmaceutical innovations. As they prepare for the forum, Trevi is hopeful that their investigational therapy can catalyze discussions around managing chronic cough and improving the quality of life for affected patients.

For more information about Trevi Therapeutics and their innovative developments, you can visit their official website at www.TreviTherapeutics.com and follow them on X (formerly known as Twitter) and LinkedIn for updates and insights.